Stockreport

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares  (KNSA) 
Last kiniksa pharmaceuticals, ltd. - class a ordinary shares earnings: 8/12 04:02 pm Check Earnings Report
PDF – ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to [Read more]